Hereditary Angioedema Therapeutics Industry Growth Expected to Reach $16.11 Billion by 2029 at a CAGR of 19.7% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Hereditary Angioedema Therapeutics Market Growth in 2025?
The market size for hereditary angioedema therapeutics has seen substantial growth in the past few years. It’s projected to expand from a valuation of $6.68 billion in 2024 to $7.84 billion in 2025, indicating a compound annual growth rate (CAGR) of 17.3%. This significant growth during the historic period can be attributed to various factors such as enhanced diagnosis and awareness, the expansion of treatment accessibility, initiatives in research and development, efforts in patient advocacy and education, and successful regulatory approvals.
What Is the Forecast for the Hereditary Angioedema Therapeutics Market Size Through 2029?
Expectations are high for the hereditary angioedema therapeutics market, as its fast-paced expansion is predicted in the coming years. The market is set to reach a valuation of $16.11 billion by 2029, with a 19.7% compound annual growth rate. This predicted growth during the forecast period can be credited to advancements in targeted therapies, global market expansion, gene therapy developments, the trend towards personalized medicine, and increased collaboration in research and treatment. The forecast period will also witness trends such as global access initiatives, health economic outcomes research, early intervention strategies, and an increase in pediatric HAE therapeutics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What are the Key Market Players in Hereditary Angioedema Therapeutics Market and How They’re Evolving?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
What Are the Primary Growth Drivers in the Hereditary Angioedema Therapeutics Market?
The hereditary angioedema market is likely to witness growth driven by the increasing rate of hereditary angioedema. This rare genetic disorder, known as Hereditary Angioedema or HAE, results in recurrent bouts of severe skin and mucous membrane swelling. The cause for such swelling is typically excess fluid accumulation or edema and can manifest in different areas of the body like hands, feet, face, intestines, and airways. To give an example, in June 2022, data from Rare Disease Advisor, a globally reaching online health care information provider, stated that hereditary angioedema affects 1 in every 50,000 people. The prevalence ranges between 1 in 10,000 to 1 in 150,000. Each year in the US, HAE episodes lead to between 15,000-30,000 ER visits. 5.8% of HAE cases are diagnosed within a 0-6 month period, while for another 5.8%, diagnosis took over 10 years. These rising instances of hereditary angioedema are thus contributing to the growth of the hereditary angioedema market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp
What Are the Leading Segments in the Global Hereditary Angioedema Therapeutics Industry?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
What Are the Key Market Trends in the Hereditary Angioedema Therapeutics Industry?
The emergence of product innovations is a prominent trend that is particularly noticeable in the hereditary angioedema therapeutics market. Industry leaders are manufacturing inventive products like gene therapy and ligand-conjugated (LICA) investigational antisense medication to maintain their status within the market. For instance, in March 2023, the USA-based biotech firm Intellia Therapeutics introduced an Investigational New Drug (IND) named NTLA-2002. The United States Food and Drug Administration gave its stamp of approval for this drug to be used in the treatment of hereditary angioedema. This approval allows the firm to broaden the scope of its ongoing Phase 1/2 trial to incorporate the United States into the Phase 2 part on a global scale. After a single dose, the therapy will permanently disable the kallikrein B1 (KLKB1) target gene, thereby substantially reducing the activity of the plasma kallikrein protein and eradicating HAE attacks. NTLA-2002 is posed to play a crucial role in in vivo genome editing.
Access The Full Report Here:
What Is the Regional Outlook for the Hereditary Angioedema Therapeutics Market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810
This Report Delivers Insight On:
1. How big is the hereditary angioedema therapeutics market, and how is it changing globally?
2. Who are the major companies in the hereditary angioedema therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the hereditary angioedema therapeutics market right now?
4. Which products or customer segments are growing the most in the hereditary angioedema therapeutics market?
5. What factors are helping or slowing down the growth of the hereditary angioedema therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
